{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:38:36Z","timestamp":1790872716179,"version":"4.1.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clonal disorders of hematopoiesis, such as myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD), affect both hematopoietic stem cells and progenitor cells within the erythroid, platelet and granulocytic lineages and can have devastating consequences in children and adults. The genetic features of these diseases often include clonal, nonrandom chromosomal deletions (e.g., 7q\u2013, 5q\u2013, 20q\u2013, 6q\u2013, 11q\u2013 and 13q\u2013) that appear to inactivate tumor suppressor genes required for the normal development of myeloid cells (reviewed in Bench1 and Fenaux2). These putative tumor suppressors have proved to be much more difficult to identify than oncogenes activated by chromosomal translocations, the other major class of chromosomal lesions in MDS and MPD.3 Although MDS and MPD are almost certainly caused by mutations in stem\/progenitor cells,4 the role of inactivated tumor suppressor genes in this process remains poorly understood. In a small portion of myeloid diseases, mutations have been identified in genes encoding factors known to be required for normal hematopoiesis, such as PU.1, RUNX1, CTNNA1 (\u03b1-catenin) and c\/EBP\u03b1, and implicating these genes as tumor suppressors.5\u20137 Nonetheless, the identities of most deletion-associated tumor suppressors in these diseases remains elusive, despite complete sequencing of the human genome. The deleted regions detected by cytogenetic methods are generally very large, containing many hundreds of genes, thus making it hard to locate the critical affected gene or genes. It is also unclear whether dysfunctional myelopoiesis results from haploinsufficiency, associated with the deletion of one allele, or from homozygous inactivation due to additional point mutations or microdeletions of the retained wild-type allele. In general MDS have proved surprisingly resistant to conventional treatments. Targeted therapeutic advances in MDS will likely depend on a full comprehension of underlying molecular mechanisms, in particular the tumor suppressor genes lost through clonal, nonrandom chromosomal deletions, such as the 7q\u2013 and (del)5q.<\/jats:p>","DOI":"10.1182\/asheducation-2005.1.156","type":"journal-article","created":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T01:29:34Z","timestamp":1132709374000},"page":"156-160","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Molecular Pathogenesis of MDS"],"prefix":"10.1182","volume":"2005","author":[{"given":"A. Thomas","family":"Look","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111701522591800_R1","doi-asserted-by":"crossref","unstructured":"Bench AJ, Nacheva EP, Champion KM, Green AR. Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol. 1998;11:819\u2013848.","DOI":"10.1016\/S0950-3536(98)80041-3"},{"key":"2019111701522591800_R2","unstructured":"Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin Hematol. 1996;33(2):127\u2013138."},{"key":"2019111701522591800_R3","doi-asserted-by":"crossref","unstructured":"Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059\u20131064.","DOI":"10.1126\/science.278.5340.1059"},{"key":"2019111701522591800_R4","doi-asserted-by":"crossref","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u2013397.","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"2019111701522591800_R5","doi-asserted-by":"crossref","unstructured":"Tenen DG. Abnormalities of the CEBP alpha transcription factor: a major target in acute myeloid leukemia. Leukemia. 2001;15(4):688\u2013689.","DOI":"10.1038\/sj.leu.2402088"},{"key":"2019111701522591800_R6","doi-asserted-by":"crossref","unstructured":"Song WJ, Sullivan MR, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166\u2013175.","DOI":"10.1038\/13793"},{"key":"2019111701522591800_R7","doi-asserted-by":"crossref","unstructured":"Mueller BU, Pabst T, Osato M, et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood. 2003;101(5):2074.","DOI":"10.1182\/blood-2002-12-3903"},{"key":"2019111701522591800_R8","doi-asserted-by":"crossref","unstructured":"Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood. 1996;88(1):358\u2013365.","DOI":"10.1182\/blood.V88.1.358.358"},{"key":"2019111701522591800_R9","doi-asserted-by":"crossref","unstructured":"Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21:255\u2013261.","DOI":"10.1038\/sj.bmt.1701084"},{"key":"2019111701522591800_R10","doi-asserted-by":"crossref","unstructured":"Arnold R, de Witte T, van Biezen A, et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant. 1998;21(12):1213\u20131216.","DOI":"10.1038\/sj.bmt.1701269"},{"key":"2019111701522591800_R11","unstructured":"Hofmann WK, Ottmann OG, Ganser F, Hoelzer D. Myelodysplastic syndromes: clinical features. Semin Hematol. 1996;33(3):177\u2013185."},{"key":"2019111701522591800_R12","doi-asserted-by":"crossref","unstructured":"Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95(5):1588\u20131593.","DOI":"10.1182\/blood.V95.5.1588.005k38_1588_1593"},{"key":"2019111701522591800_R13","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1999;17(10):3128\u20133135.","DOI":"10.1200\/JCO.1999.17.10.3128"},{"key":"2019111701522591800_R14","doi-asserted-by":"crossref","unstructured":"Kamada N, Uchino H. Preleukemic states in atomic bomb survivors in Japan. Nouv Rev Fr Hematol Blood Cells. 1976;17(1\u20132):57\u201365.","DOI":"10.1007\/978-3-642-66312-3_4"},{"key":"2019111701522591800_R15","doi-asserted-by":"crossref","unstructured":"Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994;83(12):3780\u20133786.","DOI":"10.1182\/blood.V83.12.3780.3780"},{"key":"2019111701522591800_R16","unstructured":"Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol. 1987;14(4):435\u2013443."},{"key":"2019111701522591800_R17","doi-asserted-by":"crossref","unstructured":"Tester WJ, Kinsella TJ, Waller B, et al. Second malignant neoplasms complicating Hodgkin\u2019s disease: the National Cancer Institute experience. J Clin Oncol. 1984;2(7):762\u2013769.","DOI":"10.1200\/JCO.1984.2.7.762"},{"key":"2019111701522591800_R18","doi-asserted-by":"crossref","unstructured":"Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12(12):2527\u20132534.","DOI":"10.1200\/JCO.1994.12.12.2527"},{"key":"2019111701522591800_R19","doi-asserted-by":"crossref","unstructured":"Anderson JR, Vose J, Kessinger A. Myelodysplastic syndrome after autologous transplant for lymphoma. Blood. 1994;84(11):3988\u20133989.","DOI":"10.1182\/blood.V84.11.3988.bloodjournal84113988"},{"key":"2019111701522591800_R20","doi-asserted-by":"crossref","unstructured":"Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998;92(6):1910\u20131917.","DOI":"10.1182\/blood.V92.6.1910"},{"key":"2019111701522591800_R21","unstructured":"Haas OA,Gadner H. Pathogenesis, biology, and management of myelodysplastic syndromes in children. Semin Hematol. 1996;33(3):225\u2013235."},{"key":"2019111701522591800_R22","doi-asserted-by":"crossref","unstructured":"Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567\u2013572.","DOI":"10.1182\/blood.V72.2.567.567"},{"key":"2019111701522591800_R23","doi-asserted-by":"crossref","unstructured":"Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood. 1990;76(9):1704\u20131709.","DOI":"10.1182\/blood.V76.9.1704.1704"},{"key":"2019111701522591800_R24","doi-asserted-by":"crossref","unstructured":"Warrell RP Jr., Frankel SR, Miller WH Jr., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324(20):1385\u20131393.","DOI":"10.1056\/NEJM199105163242002"},{"key":"2019111701522591800_R25","doi-asserted-by":"crossref","unstructured":"Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and the myelodysplastic syndrome. Blood. 2005;106:1207\u20131209.","DOI":"10.1182\/blood-2005-03-1183"},{"key":"2019111701522591800_R26","doi-asserted-by":"crossref","unstructured":"Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162\u20132168.","DOI":"10.1182\/blood-2005-03-1320"},{"key":"2019111701522591800_R27","doi-asserted-by":"crossref","unstructured":"Kralovics R, Passamonti F, Buser S, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u20131790.","DOI":"10.1056\/NEJMoa051113"},{"key":"2019111701522591800_R28","doi-asserted-by":"crossref","unstructured":"Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med. 1997;336(24):1713\u20131720.","DOI":"10.1056\/NEJM199706123362404"},{"key":"2019111701522591800_R29","doi-asserted-by":"crossref","unstructured":"Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol. 2001;112:118\u2013126.","DOI":"10.1046\/j.1365-2141.2001.02511.x"},{"key":"2019111701522591800_R30","doi-asserted-by":"crossref","unstructured":"Mauritzson N, Johansson B, Albin M, et al. Survival time in a population-based consecutive series of adult acute myeloid leukemia\u2014the prognostic impact of karyotype during the time period 1976\u20131993. Leukemia. 2000;14:1039\u20131043.","DOI":"10.1038\/sj.leu.2401788"},{"key":"2019111701522591800_R31","doi-asserted-by":"crossref","unstructured":"Rossi G, Pelizzari AM, Bellotti D, Tonelli M, Barlati S. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia. 2000;14:636\u2013641.","DOI":"10.1038\/sj.leu.2401711"},{"key":"2019111701522591800_R32","doi-asserted-by":"crossref","unstructured":"Andersen MK, Christiansen DH, Kirchhoff M, Pedersen-Bjergaard J. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer. 2001;31:33\u201341.","DOI":"10.1002\/gcc.1115"},{"key":"2019111701522591800_R33","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Godon C, Li JY, et al. Amplification of the 11q23 region in acute myeloid leukemia. Genes Chromosomes Cancer. 1999;26:166\u2013170.","DOI":"10.1002\/(SICI)1098-2264(199910)26:2<166::AID-GCC9>3.0.CO;2-P"},{"key":"2019111701522591800_R34","doi-asserted-by":"crossref","unstructured":"Reddy KS, Parsons L, Mak L, et al. Segmental amplification of 11q23 region identified by fluorescence in situ hybridization in four patients with myeloid disorders: a review. Cancer Genet Cytogenet. 2001;126:139\u2013146.","DOI":"10.1016\/S0165-4608(00)00406-4"},{"key":"2019111701522591800_R35","doi-asserted-by":"crossref","unstructured":"Van Limbergen H, Poppe B, Michaux L, et al. Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. Genes Chromosomes Cancer. 2002;33:60\u201372.","DOI":"10.1002\/gcc.1212"},{"key":"2019111701522591800_R36","doi-asserted-by":"crossref","unstructured":"So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell. 2003;4:99\u2013110.","DOI":"10.1016\/S1535-6108(03)00188-0"},{"key":"2019111701522591800_R37","doi-asserted-by":"crossref","unstructured":"Poppe B, Vandesompele J, Schoch C, et al. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood. 2004;103:229\u2013235","DOI":"10.1182\/blood-2003-06-2163"},{"key":"2019111701522591800_R38","doi-asserted-by":"crossref","unstructured":"Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41\u201347.","DOI":"10.1038\/ng765"},{"key":"2019111701522591800_R39","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Armstrong SA, Neuberg DS, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003;102:262\u2013268.","DOI":"10.1182\/blood-2002-10-3221"},{"key":"2019111701522591800_R40","doi-asserted-by":"crossref","unstructured":"Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17:2298\u20132307.","DOI":"10.1101\/gad.1111603"},{"key":"2019111701522591800_R41","unstructured":"Buske C, Humphries RK. Homeobox genes in leukemogenesis. Int J Hematol. 2000;71:301\u2013308."},{"key":"2019111701522591800_R42","unstructured":"Taketani T, Taki T, Shibuya N, Kikuchi A, Hanada R, Hayashi Y. Novel NUP98-HOXC11 fusion gene resulted from a chromosomal break within exon 1 of HOXC11 in acute myeloid leukemia with t(11;12)(p15;q13). Cancer Res. 2002;62:4571\u20134574."},{"key":"2019111701522591800_R43","doi-asserted-by":"crossref","unstructured":"Panagopoulos I, Isaksson M, Billstrom R, Strombeck B, Mitelman F, Johansson B. Fusion of the NUP98 gene and the homeobox gene HOXC13 in acute myeloid leukemia with t(11;12)(p15;q13). Genes Chromosomes Cancer. 2003;36:107\u2013112.","DOI":"10.1002\/gcc.10139"},{"key":"2019111701522591800_R44","doi-asserted-by":"crossref","unstructured":"Davidson AJ, Ernst P, Wang Y, et al. cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes. Nature. 2003;425:300\u2013306.","DOI":"10.1038\/nature01973"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/156\/645319\/156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/156\/645319\/156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T06:52:50Z","timestamp":1573973570000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2005\/1\/156\/19334\/Molecular-Pathogenesis-of-MDS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2005.1.156","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}